Thyroid Cancer

Selpercatinib Shows Durable Responses in Patients with Thyroid Cancer and RET Mutation
Venclexta plus Azacitidine Improves Overall Survival in Patients with AML
Advances in New Therapies Attributed to Reductions in Lung Cancer Mortality
Read More ›

On January 29, 2020, Eli Lilly announced that the FDA granted priority review to their New Drug Application for selpercatinib (LOXO-292) for the treatment of patients with advanced RET fusion-positive non–small-cell lung cancer, RET-mutant medullary thyroid cancer, and RET fusion-positive thyroid cancer. The FDA is aiming to provide its decision on the approval of selpercatinib in the third quarter of 2020. Read More ›

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: